title: Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates.
authors.affiliation: Department of Internal Medicine, University of Texas Health Sciences Center at Houston, Houston, TX.
authors.forename: Abhishek
authors.initials: A
authors.lastname: Maiti
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center at Houston, Houston, TX.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Brown
authors.affiliation: Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Paul G
authors.initials: PG
authors.lastname: Corn
authors.affiliation: Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Ravi
authors.initials: R
authors.lastname: Murthy
authors.affiliation: Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Dhakshina Moorthy
authors.initials: DM
authors.lastname: Ganeshan
authors.affiliation: Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Apostolia M
authors.initials: AM
authors.lastname: Tsimberidou
authors.affiliation: Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: vsubbiah@mdanderson.org.
authors.forename: Vivek
authors.initials: V
authors.lastname: Subbiah
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000494:pharmacology; D000068258:Bevacizumab / Q000008:administration & dosage / Q000494:pharmacology; D000069287:Capecitabine / Q000008:administration & dosage / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008297:Male; D000076225:Mechanistic Target of Rapamycin Complex 2; D008875:Middle Aged; D046912:Multiprotein Complexes / Q000235:genetics / Q000378:metabolism; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000494:pharmacology; D000077150:Oxaliplatin; D040901:Proteomics / Q000379:methods*; D017422:Sequence Analysis, DNA / Q000379:methods*; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D046912:Multiprotein Complexes; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D000069287:Capecitabine; D000076225:Mechanistic Target of Rapamycin Complex 2; D058570:TOR Serine-Threonine Kinases
keywords: Cell signaling pathways; Morphoproteomics; Refractory; Resistance; Resistant